About CELLULA BIOPHARMA, INC.
Cellula BioPharma is developing a novel CAR-T platform technology called MR-CAR for solid tumors, addressing the unmet need for effective treatments in this area. The technology has been validated through in vitro assays and tumor mouse models.
Development of MR-CAR T cell therapy for solid tumorsIn vitro assays and tumor mouse model validationNucleotide metabolic reprogramed CAR (MR-CAR) platform development
Is this your company?
Claim CELLULA BIOPHARMA, INC. to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim CELLULA BIOPHARMA, INC. & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.